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Abstract
Background Psoriatic arthritis (PsA) and co-morbidities of psoriasis represent a signiﬁcant clinical and economic bur-
den for patients with moderate-to-severe psoriasis. Often these co-morbidities may go unrecognized or undertreated.
While published data are available on the incidence and impact of some of them, practical guidance for dermatologists
on detection and management of these co-morbidities is lacking.
Objective To prepare expert recommendations to improve the detection and management of common co-morbidities
in patients with moderate-to-severe psoriasis.
Methods A systematic literature review was conducted on some common co-morbidities of psoriasis–cardiovascular
(CV) diseases (including obesity, hypertension, hyperglycaemia and dyslipidaemia), psychological co-morbidities (includ-
ing depression, alcohol abuse and smoking) and PsA–to establish the incidence and impact of each. Data gaps were
identiﬁed and a Delphi survey was carried out to obtain consensus on the detection and management of each co-mor-
bidity. The expert panel members for the Delphi survey comprised 10 dermatologists with substantial clinical expertise in
managing moderate-to-severe psoriasis patients, as well as a cardiologist and a psychologist (see appendix) with an
interest in dermatology. Agreement was deﬁned using a Likert scale of 1–7. Consensus regarding agreement for each
statement was deﬁned as ≥75% of respondents scoring either 1 (strongly agree) or 2 (agree).
Results The expert panel members addressed several topics including screening, intervention, monitoring frequency,
and the effects of anti-psoriatic treatment on each co-morbidity. Consensus was achieved on 12 statements out of 22 (3
relating to PsA, 4 relating to psychological factors, 5 relating to CV factors). The panel members felt that dermatologists
have an important role in screening their psoriasis patients for PsA and in assessing them for psychological and CV
co-morbidities. In most cases, however, patients should be referred for specialist management if other co-morbidities
are detected.
Conclusion This article provides useful and practical guidance for the detection and management of common co-mor-
bidities in patients with moderate-to-severe psoriasis.
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Introduction
Psoriasis is associated with psoriatic arthritis (PsA) and a range
of co-morbid diseases and risk factors, including obesity, meta-
bolic syndrome, cardiovascular (CV) disease, autoimmune
disease, psychiatric illness, liver disease, smoking, chronic
obstructive pulmonary disease, sleep apnoea, smoking and alco-
hol abuse.1 It should be noted that there is a greater degree of
pathophysiological/genetic association between psoriasis and
PsA than between psoriasis or PsA and their associated co-mor-
bidities. Psoriasis patients with co-morbidities are more likely to
need urgent care or hospitalisation, and incur greater total costs
than those without co-morbidities. In the United States,
compared with patients without co-morbidities, patients with
co-morbidities incurred $2184 greater costs.2
A delay in the diagnosis of PsA is a significant contributor to
poor patient outcomes, so early identification of PsA in patients
with psoriasis is important.3 There is evidence that PsA is under-
diagnosed, however, among psoriasis patients attending derma-
tology clinics.3,4 Psoriasis is linked with social stigmatisation,
pain, discomfort, physical disability, psychological distress and
financial hardship. These problems may be associated with anxi-
ety, depression, smoking and alcohol abuse, which can all also
have a direct negative impact on psoriasis and lead to poor
compliance and treatment outcomes.5 As severe psoriasis is
associated with increased mortality, and the most common cause
of death is CV disease,6 detection and management of CV dis-
ease and its risk factors may be of great importance in patients
with psoriasis.
While published data are available on the incidence and
impact of PsA and some of these co-morbidities, practical guid-
ance for dermatologists on their detection and management is
lacking. The project reported here concentrated on PsA and
certain common co-morbidities of psoriasis: psychological prob-
lems and CV diseases. A literature search was first carried out to
establish the burden of PsA and each co-morbidity. The steering
committee met to identify gaps in the literature on key topics
and to develop statements to address these gaps. A survey was
then conducted using Delphi methodology to obtain a consensus
among an international expert panel regarding screening, inter-
vention, monitoring frequency and effects of anti-psoriatic
treatment for each co-morbidity. The aim was to develop recom-
mendations to improve the detection and management of com-
mon co-morbidities in patients with moderate-to-severe psoriasis.
Methods
Literature search
A search of PubMed was carried out for articles relevant to the
selected psoriasis co-morbidities in adults, published in English
from 1 January 2005 to 31 December 2012. Search terms used
were ‘Psoriasis’ plus the secondary terms listed in Box 1. Titles
This study was developed by an unrestricted grant from Pﬁzer Inc. Medical writ-
ing support was provided by Synergy Medical.
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and abstracts of retrieved articles were scanned for relevance,
and key information on the incidence and impact of each
co-morbidity was extracted and collated. The full results of the
literature search are described in a separate publication (L. Puig,
unpublished data).
Survey participants
A steering committee, consisting of three expert dermatologists
(R. Strohal, B. Kirby and L. Puig), met to define and develop the
topics and statements for the Delphi survey. An international
expert panel, comprising 10 dermatologists with substantial clin-
ical expertise in managing patients with moderate-to-severe pso-
riasis, as well as a cardiologist with an interest in dermatology
and a psychologist who works in psychodermatology, partici-
pated in the Delphi survey.
Delphi methodology
The Delphi method was developed to enable complex problems
to be explored through structured group communication.7 It is
an evidence-based approach that allows a group to explore the
issues surrounding a problem, establishing the advantages and
disadvantages of different arguments, and clarifying ideas and
opinions.7,8 The original Delphi method has been modified to
enable achievement of consensus, through the use of surveys and
a final live meeting.9 The process involves the formation of a
steering committee responsible for identifying the issues
surrounding a complex problem, the development of relevant
survey questions and the recruitment of a panel of experts to
participate anonymously in the survey.
In this case, three rounds of anonymous completion of the
survey were followed by live meetings during which individual
survey responses remained anonymous to preserve objectivity.
At the end of the process, and through relevant scientific discus-
sion, consensus statements with regard to agreement and
disagreement were collected whenever possible.
Survey questionnaire design application
After an initial discussion of topics between members of the
expert panel, a core group developed a set of questions for the
Delphi survey, which were then reviewed by the whole group.
All of the expert panel members were then asked to complete the
online questionnaire in English. Each participant answered ques-
tions related to screening, monitoring and treating PsA and pso-
riasis co-morbidities (Box 2), grouped into PsA (six questions),
psychological factors (six questions) and CV risk factors (10
questions). These co-morbidities were chosen after a review of
the literature indicated that these have a greater impact on the
health of psoriasis patients. The questionnaire was designed to
assess the strength of agreement with statements in the defined
topic areas. This type of collaborative survey questionnaire is
able to collect and synthesize opinions across a group and
achieve a degree of consensus.
Participants scored their opinion of each statement using a
Likert scale from 1 to 7, where 1 = ‘Strongly agree’, 2 = ‘Agree’,
3 = ‘Agree somewhat’, 4 = ‘Neither agree nor disagree’,
5 = ‘Disagree somewhat’, 6 = ‘Disagree’ and 7 = ‘Strongly dis-
agree’. A numerical identification system was used to ensure that
participants remained anonymous.
After each round, the steering committee presented the survey
results to the expert panel members and a discussion took place
regarding the key issues identified and areas where consensus
had and had not been reached. After the first survey round, the
cardiologist answered only the questions relating to CV factors
and the psychologist answered only those relating to psychologi-
cal factors.
Data analysis
Following each round of completion of the questionnaires,
responses were collected and analysed on a group basis. The per-
centage of respondents assigning each Likert score was calculated
for each question. Summary statistics for each question included
the minimum, median, mode and maximum scores, as well as
an interquartile range.
To further establish the degree of agreement or disagreement,
responses to statements were categorized as ‘Agree/strongly
agree’ (score 1–2), ‘agree somewhat/neither agree nor disagree/
disagree somewhat’ (score 3–5) or ‘Disagree/strongly disagree’
(score 6–7). Consensus regarding agreement for each statement
was defined as ≥75% of respondents scoring either 1 (strongly
agree) or 2 (agree).
Results
Survey rounds and consensus
For many of the statements, responses did not change greatly
over the three rounds. For some statements, a consensus reached
in round 1 became stronger over the following rounds (Fig. 1,
top). For a few statements, the views of the experts changed con-
siderably over the three rounds, with no consensus being
reached (Fig. 1, bottom).
Following the third and final round of the survey, consensus
agreement had been reached for 12 of the 22 statements (three
relating to PsA, four relating to psychological factors and five relat-
ing to CV factors). These areas of consensus are listed in Box 3.
Psoriatic arthritis
Understanding the burden The estimated prevalence of PsA
among patients with psoriasis varies widely, from 7.7% to 73%
(Table A1),10,11 with several studies finding a prevalence
between 20% and 30%.12–14 The costs associated with PsA are
high and increase with disease severity and duration.15,16 Com-
pared with psoriasis patients without arthritis, patients with PsA
have more severe skin symptoms, a lower quality of life and
© 2013 The Authors
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greater impairment of productivity parameters.14 Increased rates
of CV risk factors, metabolic syndrome and diabetes have been
reported in PsA patients.17,18
Screening and diagnosis The first four statements about PsA
related to screening psoriasis patients for PsA. There was
100% agreement (Likert score 1–2) that all patients with pso-
riasis should be examined initially and then at least annually
for signs and symptoms of PsA. Agreement that PsA screening
questionnaires should be used routinely in dermatological
practice was also strong (92%). In discussion, the expert panel
did not come to a conclusion that any particular screening
tool could be recommended. The third statement was that
minimal standards of examination by the dermatologist should
include: examination of the hands and feet; and questioning
the patient about pain and stiffness in the joints, including
peripheral and axial pain. All of the experts agreed with
this statement. Regarding diagnosis, two-thirds of the panel
members agreed that a definitive diagnosis of PsA should be
made by a rheumatologist, but no consensus was reached on
this question.
Management/treatment The final two PsA statements related
to patient management once a diagnosis of PsA has been made.
No consensus was reached as to whether treatment decisions for
moderate-to-severe psoriatic joint symptoms can be made by
the dermatologist alone. Two-thirds of the panel members
agreed that once a diagnosis of PsA has been made, the
dermatologist can manage/treat the patient according to local
PsA treatment guidelines, but no consensus was reached.
Psychological factors
Understanding the burden The hazard ratio for depression in
psoriasis patients vs. the general population is about 1.4–1.5 and
increases with severity of psoriasis.19,20 Depression is reported in
15–62% of patients (Table 1),21,22 and suicidal ideation is
reported in 5.5% to 9.7% of psoriasis patients.23 Other psychiat-
ric diagnoses are also common.19 Psychiatric symptoms are
associated with reduced quality of life in psoriasis patients.24,25
Figure 1 Horizontal bar charts of responses for questions 1 (top) and 7 (bottom) from ﬁrst to third round Delphi questionnaire.
Table 1 Prevalence of co-morbidities in psoriasis
Co-morbidity Prevalence in psoriasis Hazard*/odds ratio
Psoriatic arthritis 8–73%10–14 –
Psychological co-morbidities
Depression 15–62%21,22 1.39*–1.4919,20
Alcohol abuse 15–30%26–29 3.10–3.6129,31
Smoking 30–51%12,30 1.31–2.9630–32
Cardiovascular co-morbidities
Obesity 8–41%12,30,50,51 1.18–5.4934
Diabetes 7–41%12,30,50 1.20–2.8034
Metabolic
syndrome
16–40%12,52 1.30–5.9234
Hypertension 13–50%21,30,50,53,54 1.09–3.2734
Dyslipidaemia 6–61%2,30,53,54 1.00–2.0934
*Hazard ratio.
© 2013 The Authors
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Alcohol abuse is reported in 15–30% of psoriasis patients.26–29
There is little evidence for an association between alcohol
consumption and severity of psoriasis, but excess alcohol
consumption appears to be associated with depression in psoria-
sis patients,26,28 and may adversely affect treatment outcomes,
particularly regarding poor compliance.28 Psoriasis patients have
an increased likelihood of smoking compared with the general
population, with odds ratios from 1.31 to 2.96 reported.30–32
Smoking is also associated with psoriasis disease severity,29,32
and is correlated with impaired psoriasis-related quality of life.33
All of these addictive behaviours may be related to the
emotional burden of the psoriasis patient having a stigmatising
disease.
Assessment and referral There was strong agreement (92%
with Likert score 1–2) that patients with moderate-to-severe
psoriasis should be assessed regularly for anxiety, depression and
addictive behaviour (e.g. alcohol consumption, smoking). The
panel members tended to disagree however (50% scored 6–7)
with the statement, that for psoriasis, all relevant psychological
co-morbidities are covered by the dermatology life quality index
(DLQI). Consensus was reached on each of the next three state-
ments regarding psychiatric referral: there was strong agreement
(92% with Likert score 1–2) that the patient should be referred
to a psychiatrist if psychological co-morbidities substantially
impact the management of moderate-to-severe psoriasis or if the
dermatologist suspects depression. Agreement was very strong
(100% with Likert score 1–2) that if the dermatologist suspects
severe depression, the patient should be referred to a psychia-
trist.
Management/treatment The final statement in this section was
that specific therapeutic interventions for psychological co-mor-
bidities can be performed by the dermatologist. Opinion was
divided, with more than half of the panel members disagreeing
with this statement.
Cardiovascular factors
Understanding the burden Table A1 shows estimates from lit-
erature of the prevalence of various CV risk factors in patients
with psoriasis. In a systematic review published in 2010, all but
one of eight studies on obesity found an increased risk in psoria-
sis patients, with odds ratios ranging from 1.18 (95% CI 1.14–
1.23) to 5.49 (3.09–9.74).34 The risk increased with severity of
psoriasis. The same review found an increased risk of metabolic
syndrome in three of three studies, with odds ratios ranging
from 1.3 (1.1–1.4) to 5.92 (2.78–12.8).34 A significant association
of psoriasis with diabetes was found in 11/14 studies (odds ratio
1.20 [1.14–1.25] to 2.80 [2.68–2.99]), with dyslipidaemia in 7/12
studies (1.0 [1.0–1.3] to 2.09 [1.23–3.54]) and with hypertension
in 10/12 studies (1.09 [1.05–1.14] to 3.27 [2.41–4.43]).34 Two
meta-analyses published since the literature search was
performed found odds ratios of 1.58 (95% CI 1.42–1.76) for
hypertension and 1.59 (1.38–1.83) for type 2 diabetes among
patients with psoriasis compared with controls.35,36 Both found
higher odds among patients with severe psoriasis.
A cross-sectional study found that the Framingham risk score
was significantly higher in patients with psoriasis than in con-
trols at 5 years (5.3  4.4 [mean  SD] vs. 3.4  3.3, P <
0.001) and at 10 years (11.2  8.1 vs. 7.3  6.3, P < 0.001).37
Data on cardiac events in psoriasis patients are limited. One
cohort study noted a significantly increased risk of major CV
adverse events in patients with severe psoriasis.38 A recent meta-
analysis of nine studies suggests that severe psoriasis significantly
increases the risk of CV mortality (relative risk 1.39, 95% CI,
1.11–1.74), myocardial infarction (relative risk 1.70, 95% CI
1.32–2.18) and stroke (relative risk 1.56, 95% CI, 1.32–1.84).39 A
large case–control study found an increased risk of CV death in
psoriasis patients.6
Monitoring and assessment The expert panel recognized the
importance of assessing and reducing CV risk in patients with
moderate-to-severe psoriasis. There was 100% agreement that
patients with moderate-to-severe psoriasis should have the
following monitored initially and annually thereafter: blood
pressure, body mass index (BMI), waist circumference, lipids
(e.g., cholesterol, triglycerides, low-density/high-density lipopro-
tein cholesterol), fasting glucose, glycosylated haemoglobin
(HbA1c), smoking status. There was also good agreement (83%
scored 1–2) that moderate-to-severe psoriasis is an independent
risk factor for CV disease and that intervention thresholds
should be adjusted accordingly (as recommended for patients
with rheumatoid arthritis).40 The same proportion of the panel
members agreed that aggressive management of CV risks is
necessary in patients with moderate-to-severe psoriasis.
No consensus was reached on the next three statements:
• Dermatologists should use CV risk scores to assess patients
with moderate-to-severe psoriasis.
• Referral to a specialist should be based on the European
Society of Cardiology CV risk scoring charts, as assessed by
the dermatologist.
• Referral to a specialist should be based solely on abnormal
CV parameters, as assessed by the dermatologist.
Management/treatment According to the expert panel, weight
loss and lifestyle advice should be given by dermatologists dur-
ing the routine management of patients with moderate-to-severe
psoriasis (83% scored 1–2). The panel felt that treatment choices
for CV co-morbidities should be determined by a cardiologist,
endocrinologist or family doctor (91% scored 1–2). Most of the
panel members (58.4% [consensus not reached]) did not agree
that management of CV issues should be performed by the
dermatologist, according to ESC guidelines. Two-thirds of the
© 2013 The Authors
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experts considered that more intensive systemic treatment for
moderate-to-severe psoriasis is needed in patients with increased
CV risk factors, but consensus was not reached on this subject.
Discussion
Co-morbidities of psoriasis represent a significant burden for
patients. A recent US population-based study found that the
mean Carlson co-morbidity index was increasingly higher
among patients with mild, moderate and severe psoriasis
compared with matched controls.41 However, co-morbidities
may often go unrecognized or undertreated. The Delphi survey
reported here enabled consensus to be reached on 12 statements
regarding the detection and management of PsA and of impor-
tant psychological and CV co-morbidities in patients with
moderate-to-severe psoriasis (Box 3).
The three consensus statements on PsA all related to screening
and detection. The experts were unanimous in considering that
all psoriasis patients should be examined at least annually for
signs and symptoms of PsA, and that this should include exami-
nation of the hands and feet as well as questioning the patient
about pain and stiffness in the joints. The Group for Research
and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
considers inflammation to include such features as pain involv-
ing joints, spine and/or entheses associated with erythema,
warmth and swelling, and prominent morning and rest stiff-
ness.43 The panel also strongly agreed that PsA screening ques-
tionnaires should be used routinely in dermatology clinical
practice. Tools available include the Psoriatic and Arthritis
Questionnaire (PAQ),43 the Psoriasis Epidemiology Screening
Tool (PEST),44 the Psoriatic Arthritis Screening and Evaluation
(PASE),45 the Toronto Psoriatic Arthritis Screening (ToPAS)46
and the Early ARthritis for Psoriatic patients (EARP) question-
naire.47 However, all of these instruments have deficiencies,3,48
and more work is needed before specific recommendations can
be made about which one to use.
Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis recommends that diagnosis of PsA should follow the
Classification Criteria for Psoriatic Arthritis (CASPAR) crite-
ria.42,49 Whether the definitive diagnosis is made by the derma-
tologist or a rheumatologist will depend on the local situation
and the expertise of the dermatologist. Some cases are easier to
diagnose than others, and opinions will be influenced by the
local availability of rheumatologists. The diagnosis of PsA
requires a structured examination, and dermatologists can be
competent in doing this. Many dermatologists will also be confi-
dent in treating PsA with a tumour necrosis factor inhibitor,
while others may prefer to refer patients to a rheumatologist for
consideration of treatment with a disease-modifying anti-rheu-
matic drug or a biological.
The expert panel recognized the importance of regularly
assessing psoriasis patients for anxiety, depression and addictive
behaviour. The frequency of assessment was not specified in the
survey question, but the experts felt that annual assessment
would be appropriate. They considered formal assessment to be
necessary, as dermatologists are often not aware of psychological
problems in their patients. The panel did not believe that derma-
tologists should be performing therapeutic interventions for psy-
chological co-morbidities, recommending that patients with
such co-morbidities, including depression, should be referred
for specialist management. As smoking appears to be associated
with psoriasis disease severity28,32 and is correlated with
impaired psoriasis-related quality of life,33 smoking cessation
should be considered a priority in patients with psoriasis.
Rheumatoid arthritis is considered an independent risk factor
for CV disease, requiring intervention targets to be adjusted
accordingly and aggressive management of CV risk factors.40
The expert panel agreed that the same approach proposed by the
European League Against Rheumatism (EULAR) for CV disease
risk management in patients with PsA should be taken in mod-
erate-to-severe psoriasis. Psoriasis patients should have their
blood pressure, BMI, waist circumference, lipids, fasting glucose,
HbA1c and smoking status monitored on an annual basis. The
experts felt that such monitoring is warranted, even in younger
patients, given the high CV impact of psoriasis. It is less clear
who should do the monitoring; it may be the dermatologist or
the family doctor. If dermatologists are going to do this, they
will need to become more familiar with the use of CV risk
scores. The experts felt that dermatologists should give weight
loss and other lifestyle advice to their psoriasis patients, but
treatment choices for CV co-morbidities should be determined
by other specialists or the family doctor.
This consensus article provides useful and practical guidance
for the detection and management of common co-morbidities
in patients with moderate-to-severe psoriasis. It also highlights
areas where consensus was not reached and further research is
clearly needed to optimize patient management.
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Appendix
The following experts also took part in the Delphi survey: Prof.
Peter Riis Hansen (Cardiologist), Gentofte Hospital, Copenha-
gen, Denmark Sandra Ros (Psychologist), Hospital de la Santa
Creu i Sant Pau, Barcelona, Spain.
Box 1. Terms used in literature search
“Psoriasis” plus:
• Cardiovascular risk factors
• Obesity/body mass index
• Diabetes/insulin sensitivity/resistance
• Metabolic syndrome
• Hypertension/blood pressure
• Dyslipidaemia/cholesterol/triglycerides/lipid profile/hy-
perlipidaemia
• Major adverse cardiac events/myocardial infarction/
stroke/coronary heart disease
• Paediatric + each of above terms
• Alcohol abuse/misuse/intake
• Smoking
• Depression/anxiety/psychiatric/psychosocial/mental
health
• Paediatric + depression/anxiety/psychiatric/psychoso-
cial/mental health
• Sexual dysfunction/function
• Sleep/sleep apnoea
Box 2. Questions asked in the Delphi survey
Psoriatic arthritis (PsA)
1 All patients with psoriasis should be examined initially
and then at least annually for signs and symptoms of PsA.
2 In principle, the routine use of PsA screening question-
naires may be useful.
3 Minimal standards of examination by the dermatologist
should include:
• Examination of the hands and feet
• Questioning the patient about pain and stiffness in the
joints, including peripheral and axial pain.
4 A definitive diagnosis of PsA should be made by a rheu-
matologist.
5 Treatment decisions for moderate-to-severe psoriatic
joint symptoms can be made by the dermatologist alone.
6 Once a diagnosis of PsA has been made, the dermatologist
can manage/treat the patient as per local PsA treatment
guidelines.
Psychological factors
7 For psoriasis, all relevant psychological co-morbidities are
covered by the Dermatology Life Quality Index (DLQI)
or other quality of life scores.
8 Patients with moderate-to-severe psoriasis should be
assessed regularly for anxiety, depression and addictive
behaviour.
9 If psychological co-morbidities substantially impact the
management of moderate-to-severe psoriasis, the patient
should be referred to a psychiatrist.
10 If the dermatologist suspects severe depression, the
patient should be referred to a psychiatrist.
11 Specific therapeutic interventions for psychological
co-morbidities can be performed by the dermatologist.
Cardiovascular factors
12 Patients with moderate-to-severe psoriasis should have
the following monitored initially and annually thereaf-
ter:
• Blood pressure
• Body mass index (BMI)
• Waist circumference
• Lipids
(i) Cholesterol
(ii) Triglycerides
(iii) Low-density lipoprotein (LDL)/high-density lipo-
protein (HDL)
• Fasting glucose
• Glycated haemoglobin (HbA1c)
• Smoking status
13 Moderate-to-severe psoriasis is an independent risk fac-
tor for cardiovascular disease; intervention thresholds
should be adjusted accordingly (as they are for rheuma-
toid arthritis [RA]).
14 RA data suggest that aggressive management of cardio-
vascular risks is necessary. Cardiovascular risk manage-
ment should also be adjusted in patients with moderate-
to-severe psoriasis.
15 Dermatologists should use cardiovascular risk scores to
assess patients with moderate-to-severe psoriasis.
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16 Referral to a specialist should be based on an appropri-
ate cardiovascular scoring system, as assessed by the der-
matologist.
17 Referral to a specialist should be based solely on abnor-
mal cardiovascular parameters, as assessed by the derma-
tologist.
18 Treatment choices for cardiovascular co-morbidities
should be determined by a cardiologist, endocrinologist
or family doctor.
19 Management of cardiovascular issues should be per-
formed by the dermatologist, according to European
guidelines.
20 In patients with increased cardiovascular risk factors,
more intensive systemic treatment for moderate-to-
severe psoriasis is appropriate.
21 Weight loss and lifestyle advice must be given by derma-
tologists during the routine management of patients
with moderate-to-severe psoriasis.
Box 3. Consensus statements on co-morbidities of mod-
erate-to-severe psoriasis
Psoriatic arthritis (PsA)
• All patients with psoriasis should be examined initially
and then at least annually for signs and symptoms of
PsA
• PsA screening questionnaires should be used routinely
in dermatology clinical practice
• Minimal standards of examination by the dermatologist
should include:
○ Examination of the hands and feet
○ Questioning the patient about pain and stiffness in the
joints, including peripheral and axial pain
Psychological factors
• Patients with moderate-to-severe psoriasis should be
assessed regularly for anxiety, depression and addictive
behaviour
• If psychological co-morbidities substantially impact the
management of moderate-to-severe psoriasis, the
patient should be referred to a psychiatrist
• If the dermatologist suspects (severe) depression, the
patient should be referred to a psychiatrist
Cardiovascular factors
• Patients with moderate-to-severe psoriasis should have
the following monitored initially and annually thereafter:
○ Blood pressure, BMI, waist circumference, lipids (e.g.,
cholesterol, triglycerides, low-density/high-density
lipoprotein), fasting glucose, glycated haemoglobin
(HbA1c), smoking status
• Moderate-to-severe psoriasis is an independent risk fac-
tor for cardiovascular disease; intervention thresholds
should be adjusted accordingly (as they are for rheuma-
toid arthritis)
• RA data suggest that aggressive management of cardio-
vascular risks is necessary. Cardiovascular risk manage-
ment should also be adjusted in patients with moderate-
to-severe psoriasis
• Treatment choices for cardiovascular co-morbidities
should be determined by a cardiologist, endocrinologist
or family doctor
• Weight loss and lifestyle advice must be given by derma-
tologists during the routine management of patients
with moderate-to-severe psoriasis
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